LTTS is an engineering services provider incorporated in 2012, offers engineering,, research and development (ER&D) and digitalization solutions to companies in the
L&T Technology Services Ltd Q4FY25; 9% fall in Profits
Categories
research and development
L&T Technology Services Ltd Q2FY25; 5% fall in Profits
LTTS is an engineering services provider incorporated in 2012, offers engineering,, research and development (ER&D) and digitalization solutions to companies in the
Sun Pharma Advanced Research Company Ltd Q4FY24; 65% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
L&T Technology Services Ltd Q4FY24; 7% rise in Revenue
LTTS is an engineering services provider incorporated in 2012, offers engineering, research and development (ER&D) and digitalization solutions to companies in the
Sun Pharma Advanced Research Company Ltd Q3FY24; 89% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
Sun Pharma Advanced Research Company Ltd Q2FY24; 34% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
Zim Laboratories Ltd Q1FY24; 96% fall in Profits
Zim Laboratories Limited is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these
Torrent Pharmaceuticals Ltd Q1FY24; 7% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Sun Pharma Advanced Research Company Ltd Q1FY24; 14% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
Syngene reported 21 percent rise in its Q4FY23 net profit
Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.While, consolidated
Syngene International Q4FY23 results out, revenue rises by 31%
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Sun Pharma Advanced Research Q3FY23 Earnings
(SPARC) Sun Pharma Advanced Research Company Limited conducts pharmaceutical product research and development (R&D). Financial Results: After nine consecutive quarters of losses,
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Shares of Biocon research arm soars as it reports 23% rise in its revenue
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
IPO Alert: Aether Industries files for initial public offering
The global chemicals market was valued at around $5,027 billion in 2020, with India enjoying a market share of 4% that represents